Abivax (NASDAQ:ABVX) Trading Down 4% – Should You Sell?

Abivax SA Sponsored ADR (NASDAQ:ABVX) shares traded down 4% on Tuesday . The stock traded as low as $134.26 and last traded at $134.80. 422,172 shares changed hands during mid-day trading, a decline of 52% from the average session volume of 880,448 shares. The stock had previously closed at $140.40.

Analysts Set New Price Targets

A number of equities analysts recently commented on ABVX shares. Truist Financial set a $140.00 price target on Abivax in a research note on Monday, November 24th. Barclays started coverage on Abivax in a research report on Monday, October 13th. They issued an “overweight” rating and a $142.00 target price for the company. Citigroup reissued an “outperform” rating on shares of Abivax in a research report on Tuesday, December 16th. Wall Street Zen lowered shares of Abivax from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. Finally, Wolfe Research upgraded shares of Abivax to a “strong-buy” rating in a research report on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $128.73.

Abivax Trading Down 2.0%

The firm’s fifty day moving average price is $114.53 and its 200-day moving average price is $78.02. The company has a market cap of $10.72 billion, a price-to-earnings ratio of -32.89 and a beta of 0.49. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.86 and a quick ratio of 7.86.

Abivax (NASDAQ:ABVX) last issued its quarterly earnings data on Monday, December 15th. The company reported ($2.46) earnings per share for the quarter. The company had revenue of ($4.92) million for the quarter. On average, equities analysts expect that Abivax SA Sponsored ADR will post -2.83 EPS for the current fiscal year.

Hedge Funds Weigh In On Abivax

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ABVX. Kennedy Capital Management LLC increased its holdings in shares of Abivax by 7.1% during the second quarter. Kennedy Capital Management LLC now owns 241,188 shares of the company’s stock valued at $1,845,000 after purchasing an additional 15,997 shares during the period. Quadrature Capital Ltd acquired a new position in Abivax during the 2nd quarter valued at about $148,000. Simplify Asset Management Inc. bought a new stake in shares of Abivax during the 3rd quarter worth about $5,217,000. Octagon Capital Advisors LP acquired a new stake in shares of Abivax in the 1st quarter worth approximately $7,688,000. Finally, Saturn V Capital Management LP boosted its holdings in shares of Abivax by 12.6% in the second quarter. Saturn V Capital Management LP now owns 622,479 shares of the company’s stock valued at $4,762,000 after acquiring an additional 69,553 shares in the last quarter. 47.91% of the stock is owned by institutional investors.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.